SOURCE: Janus Pharmaceuticals, Inc.

August 18, 2005 11:00 ET

Janus Pharmaceuticals Inc. Featured on the Wall Street Reporter

PASADENA, CA -- (MARKET WIRE) -- August 18, 2005 -- Janus Pharmaceuticals Inc., an emerging specialty pharmaceutical company focused on dermatology and infectious disease products, announced today that they were featured in an exclusive interview conducted by Ian Roberts, Senior Analyst with the Wall Street Reporter. Company President Carolyn Siegal was invited to discuss the company's recent accomplishments and current fundraising activities. Prospective investors are invited to listen to the interview via a link on the company's website,

According to Ms. Siegal, "This interview allowed the company to share both our most significant accomplishments in 2005 and our vision for the future with potential investors. We are building the leading topical anti-infectives company, and this is a valuable opportunity for the investment community to learn more about us."

Janus is a privately held company founded in September 2004 pursuing the clinical development and commercialization of new drugs for the treatment of dermatological manifestations of infectious diseases including bacterial, fungal and viral infections.

Janus currently has three products in development, JA-001, a topical formulation of a widely studied antiviral product for treatment of shingles (herpes zoster), JA-002, a gel formulation of a novel proprietary antibiotic targeting prevention and treatment of bacterial infections of the skin including resistant pathogens, and JA-003, an antibiotic cream for the treatment of acne. Janus is also actively pursuing the acquisition of additional products which will complement their growing product portfolio.


Contact Information

  • Contact:
    Carolyn Siegal